ASPIC

send to a friend share this

Beatson International Cancer Conference: Modelling the Mechanisms of Malignancies - In Vivo Veritas

Glasgow University, Glasgow, United Kingdom

 

03-06 July, 2016

 

See more informations here: http://www.beatson.gla.ac.uk/beatson-conference/beatson-international-cancer-conference.html

Iº Porto Precision Oncology Meeting

Auditorio da Universidade Fernando Pessoa, Porto, Portugal

 

10-11 March, 2016

 

See more informations here: http://www.factorchave.com/pt/1-porto-oncology-precision-meeting

Iº Porto Precision Oncology Meeting

Auditório da Universidade Fernando Pessoa, Porto, Portugal

 

10-11 March, 2016

 

See more informations here: http://www.factorchave.com/pt/1-porto-oncology-precision-meeting

NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer

 

Prostate cancer (PCa) remains a major health burden in men, being the second most common non-skin cancer and the fifth leading cause of death from cancer worldwide. Despite the use of serum prostate-specific antigen (PSA) as an important clinical tool for early PCa detection, this test has many shortcomings and has limited prognostic value. Therefore, there is a need of more reliable diagnostic markers to complement PSA, as well as better prognostic markers to differentiate aggressive from indolent tumors.

NCOA2 é um candidato a gene alvo do ganho do 8q associado a cancro da próstata clinicamente agressivo

O cancro da próstata (CaP) constitui um grande problema de saúde para os homens, sendo o segundo tipo de cancro mais comum e a quinta causa de morte por cancro em todo o mundo. Apesar do uso do PSA como ferramenta clínica para a detecção precoce do CaP, este teste tem muitas falhas e o seu valor de prognóstico é limitado.

Seminar «Cancer Prevention and Control Research in Puerto Rico: a focus on HPV and HIV»

ISPUP Auditorium, Porto, Portugal

 

8 February, 2016

 

See more informations here: http://ispup.up.pt/news/internal-news/ispup-seminar-18-12-2015/347.html/

Seminar «Cancer Prevention and Control Research in Puerto Rico: a focus on HPV and HIV»

ISPUP Auditorium, Porto, Portugal

 

8 February, 2016

 

See more informations here: http://ispup.up.pt/news/internal-news/ispup-seminar-18-12-2015/347.html/

Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma

Osteopontin (OPN) is a multifunctional protein frequently overexpressed, and involved in tumour progression in different types of cancer. In this study, we found that OPN is expressed in medullary thyroid carcinoma (MTC), C cell hyperplasia and C cells, and at variance with other cancers, OPN expression is associated with good prognostic features and cell differentiation. 

 

Authors and Affiliations:

A expressão da osteopontina está correlacionada com diferenciação e bom prognóstico em carcinoma medular da tireoide

A osteopontina (OPN) é uma proteína multifuncional frequentemente sobreexpressa e associada com a progressão tumoral em diferentes tipos de cancro. Neste trabalho verificamos que a OPN é expressa em carcinoma medular da tireoide (CMT), hiperplasia de células C e em células C, e que ao contrário do que ocorre em outros tipos de cancro, em CMT a OPN está associada com características de bom prognóstico e diferenciação celular. 

 

Autores e Afiliações:

Long non-coding RNAs at the service of the tumor suppressor p53

Authors and Affiliations:

Melo CA1, Léveillé N1, Rooijers K1, Wijchers PJ2, Geeven G2, Tal A1, Melo SA3, de Laat W2, Agami R1,4.

1Division of Biological Stress Response, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

2Hubrecht Institute-KNAW and University Medical Centre Utrecht, Utrecht, The Netherlands.